Globus Medical, Inc. $GMED Shares Acquired by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH increased its holdings in shares of Globus Medical, Inc. (NYSE:GMED) by 11.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 356,811 shares of the medical device company’s stock after purchasing an additional 37,220 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Globus Medical were worth $30,743,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the stock. Invesco Ltd. raised its position in Globus Medical by 1,235.2% in the fourth quarter. Invesco Ltd. now owns 3,886,405 shares of the medical device company’s stock valued at $339,322,000 after purchasing an additional 3,595,339 shares during the period. Bank of Montreal Can boosted its position in shares of Globus Medical by 15,317.1% in the fourth quarter. Bank of Montreal Can now owns 3,373,260 shares of the medical device company’s stock worth $294,519,000 after buying an additional 3,351,380 shares during the period. William Blair Investment Management LLC grew its stake in shares of Globus Medical by 17.2% in the third quarter. William Blair Investment Management LLC now owns 2,819,165 shares of the medical device company’s stock valued at $161,454,000 after buying an additional 414,134 shares in the last quarter. Sculptor Capital LP grew its stake in shares of Globus Medical by 31.9% in the second quarter. Sculptor Capital LP now owns 2,760,688 shares of the medical device company’s stock valued at $162,936,000 after buying an additional 667,850 shares in the last quarter. Finally, Madison Avenue Partners LP raised its holdings in shares of Globus Medical by 3.0% during the 4th quarter. Madison Avenue Partners LP now owns 2,624,751 shares of the medical device company’s stock valued at $229,167,000 after buying an additional 76,588 shares during the period. 95.16% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, June 5th. The shares were sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the completion of the sale, the director owned 510,175 shares of the company’s stock, valued at approximately $41,201,733. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 18.38% of the company’s stock.

Globus Medical Stock Performance

NYSE:GMED opened at $86.05 on Monday. The stock has a market cap of $11.68 billion, a price-to-earnings ratio of 20.01, a price-to-earnings-growth ratio of 1.78 and a beta of 0.95. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40. The business’s 50-day simple moving average is $83.58 and its 200 day simple moving average is $87.40.

Globus Medical (NYSE:GMED) last issued its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating analysts’ consensus estimates of $0.92 by $0.20. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. During the same quarter last year, the firm earned $0.68 EPS. Globus Medical’s quarterly revenue was up 27.0% on a year-over-year basis. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities research analysts predict that Globus Medical, Inc. will post 4.74 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts recently commented on GMED shares. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, March 3rd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Wall Street Zen cut shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Needham & Company LLC upped their target price on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a research note on Friday, May 8th. Finally, Piper Sandler lowered their price target on shares of Globus Medical from $115.00 to $100.00 and set an “overweight” rating for the company in a report on Monday, June 15th. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $105.00.

Globus Medical Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.